Published in Cancer Weekly, May 4th, 1998
David L. Corbet, Matritech, said, "We are very excited about their strong marketing capabilities as they relate to selling NMP22 in Spain."
"We wanted a bladder cancer tumor marker to add to our diagnostic portfolio which complements our bladder cancer therapy, BCG. We are extremely pleased to have concluded a distribution agreement for NMP22, which we believe...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.